CTLA4 and neoplasm: Moreover, in the poorly immunogenic B16.F10 model, adding ADU-S100 to the ineffective combination therapy of anti-PD-1 and anti- CTLA-4 induced tumor-specific CD8+ T cell responses and tumor control, leading to multiple complete responses and durable immunity in surviving animals.